October 24, 2016
Genotype 2 accounts for about 9% of all hepatitis C infections worldwide. It is the most common type of infection in West Africa, although the greatest number of cases is in East Asia where it is less common but still represents a sizable percentage of all infections. In the United States, genotype 2 accounts for nearly 15% of infections.
In the prior era of peginterferon and ribavirin treatments, patients with genotype 2 infections were the easiest to treat. Today, even higher cure rates exist with new direct-acting antivirals. The best option is the one-pill combination of sofosbuvir/velpatasvir. An alternative is the combination of sofosbuvir and daclatasvir (Daklinza).
Credit: naruedom for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|